Clinical trials: B ALL
Multiple Myeloma
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with that of combination of pomalidomide, bortezomib and dexamethasone in Japanese participants…
- Trial name
- DREAMM 8 (NCT06956170)
- Testing
- Belantamab mafodotin, Pomalidomide, Dexamethasone
- Where
- 13 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
Lymphoma, Mantle Cell Lymphoma
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells, either…
- Conditions
- Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, SLL
- Trial name
- VCR (NCT00980395)
- Testing
- rituximab, bortezomib, cladribine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Arizona
Lymphoma
Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma
The goals of this protocol are to determine the effect of oxaliplatin, cytosine arabinoside, and dexamethasone with Rituxan (ROAD) as treatment for patients with relapsed CD20+ B-cell non-Hodgkins lymphoma (NHL).
- Trial name
- NCT00166439
- Testing
- Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Academic and Community Cancer Research United
Healthy, Premature Ovarian Failure
Feasibility Study for Development of an Early Test for Ovarian Failure
This purpose of this study is to gain information about normal ovarian function that will be useful in developing a test for early detection of ovarian failure.
- Trial name
- NCT00006156
- Testing
- Control, Drug: FSH
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Chronic Lymphocytic Leukemia
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
Phase 2, two cohort trial evaluating the addition of ublituximab and umbralisib on the rate of minimal residual disease (MRD) negativity in participants with Chronic Lymphocytic Leukemia (CLL), who are currently on treatment with…
- Trial name
- NCT04016805
- Testing
- Ublituximab, Umbralisib, Ibrutinib
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- TG Therapeutics, Inc.
Follicular Lymphoma, Marginal Zone Lymphoma
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
Ofatumumab is a drug that works by attaching to the CD20 molecule found on the surface of cancerous B cells, and then triggering the death of those cells.
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT01239394
- Testing
- ofatumumab
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- Massachusetts General Hospital
Diffuse Large B-Cell Lymphoma
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in combination with various agents for the treatment of Relapsed/Refractory (R/R)…
- Trial name
- Javelin DLBCL (NCT02951156)
- Testing
- Avelumab, Utomilumab, Rituximab
- Where
- 29 sites in United States, Australia and 6 more
- Volunteers
- 29 people
- Sponsor
- Pfizer
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
A Phase 3 clinical trial to examine the efficacy of duvelisib monotherapy versus ofatumumab monotherapy in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
- Trial name
- NCT02004522
- Testing
- Duvelisib, Ofatumumab
- Where
- 92 sites in United States, Australia and 9 more
- Volunteers
- 319 people
- Sponsor
- SecuraBio
Chronic Hepatitis B
Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B
A randomized, open-label multicentre clinical trial of daily Myrcludex B versus entecavir in patients with HBeAg negative chronic hepatitis B.
- Trial name
- NCT02881008
- Testing
- Entecavir, Myrcludex B
- Where
- 9 sites in Russia
- Volunteers
- 48 people
- Sponsor
- Hepatera Ltd.
Stage III Diffuse Large B-Cell Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma
Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission
The purpose of this study is to evaluate pidilizumab and its effect, bad and/or good, on the immune system in relation to its ability to fight cancer cells.
- Trial name
- NCT02530125
- Testing
- Laboratory Biomarker Analysis, Pidilizumab
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Northwestern University
Lymphoid Leukemia, Acute Lymphoblastic Leukemia
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
This study involves Vyxeos (CPX-351), a formulation of a fixed combination of the two anti-tumor drugs, cytarabine and daunorubicin that will be given as an infusion over 90 minutes.
- Conditions
- Lymphoid Leukemia, Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
- Trial name
- NCT03575325
- Testing
- CPX-351
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00755040
- Testing
- cyclosporine ophthalmic emulsion
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lymphoma
Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)
RATIONALE: Imaging procedures, such as positron emission tomography or computed tomography, may help in detecting differences between Hodgkin lymphoma or diffuse large B-cell lymphoma cancer cells.
- Trial name
- NCT01004718
- Testing
- Fludeoxyglucose F18, Computed Tomography, Positron emission tomography
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Gastrointestinal Neoplasms, Cholangiocarcinoma
A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer
Phase 1a - Explore safety and establish the maximum tolerated dose (MTD)/recommended dose levels for phase Ib expansion phase of BI 905711 based on the frequency of patients experiencing dose limiting toxicities (DLTs) during the…
- Conditions
- Gastrointestinal Neoplasms, Cholangiocarcinoma, Pancreatic Neoplasms
- Trial name
- NCT04137289
- Testing
- BI 905711
- Where
- 18 sites in United States, Belgium and 6 more
- Volunteers
- 110 people
- Sponsor
- Boehringer Ingelheim
Fluid Over-load
B-type Natriuretic Peptide as a Surrogate Marker Guiding Post-operative Fluid Off-loading
The long-range goal of this proposal is to decrease morbidity and mortality related to pulmonary edema and congestive heart failure (CHF) in post-operative patients.
- Trial name
- NCT01584518
- Testing
- Furosemide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Creighton University
Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00736450
- Testing
- oblimersen sodium, rituximab, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Nebraska
Meningitis, Meningococcal, Serogroup B
Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age
This study will assess the safety, tolerability and immunogenicity of bivalent rLP2086 vaccine in laboratory workers ≥18 to ≤65 years of age administered on a Month 0, 2, and 6 schedule.
- Trial name
- B1971042 (NCT01768117)
- Testing
- rLP2086
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Pfizer
Follicular Lymphoma (FL), CLL
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
- Conditions
- Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome
- Trial name
- KEYNOTE145 (NCT02362035)
- Testing
- Acalabrutinib, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 161 people
- Sponsor
- Acerta Pharma BV
Lymphoma, Large-Cell, Diffuse
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
This study is being conducted to compare the efficacy and safety of ofatumumab in addition to salvage chemotherapy versus rituximab in addition to salvage chemotherapy in CD20 positive DLBCL subjects relapsing, or with persistent…
- Trial name
- ORCHARRD (NCT01014208)
- Testing
- OFATUMUMAB + DHAP, RITUXIMAB + DHAP
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 447 people
- Sponsor
- GlaxoSmithKline
Haemophilia B
A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B
The study investigates how well the medicine called nonacog beta pegol (N9-GP) works in Chinese people with haemophilia B. Participants will be treated with N9-GP.
- Trial name
- Paradigm9 (NCT05365217)
- Testing
- Nonacog beta pegol
- Where
- 15 sites in China
- Volunteers
- 30 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.